MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

$FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma$

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

IRBM Expands Functional Genomics Platform for Early Drug Discovery

03 Apr 2025

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug...

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

Align Technology Supports Children and Teens With 30 Invisalign® Treatments via Smiles4Canada Program

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

By Merck & Co., Inc
Merck & Co., Inc
06 Aug 2026

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

By Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
05 Aug 2026

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

By SHARx
SHARx
04 Aug 2026

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

By Triquetra Health LLC
Triquetra Health LLC
03 Aug 2026

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

By Resbiotic Nutrition, Inc.
Resbiotic Nutrition, Inc.
03 Aug 2026

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

By US Capital Global
US Capital Global
03 Aug 2026

The Digital Pharma Advances Conference 2026

Most Popular

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

By Formosa Pharmaceuticals Inc

May 09
Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

By Biotheryx, Inc.

Jul 17
The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

By Clarity Pharmaceuticals

Oct 14

August 2026

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Search your requirement

Social media

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

IRBM Expands Functional Genomics Platform for Early Drug Discovery

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

Align Technology Supports Children and Teens With 30 Invisalign® Treatments via Smiles4Canada Program

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

Most Popular

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

User Area

Discover

Engage with Us

Search your requirement

Social media

Featured Press Releases

Most Popular

User Area

Discover

Engage with Us

Subscribe to Our Monthly Newsletter